《大行報告》大和降百勝中國(09987.HK)目標價至432元 評級「買入」
大和發表研究報告指,百勝中國(09987.HK)(YUMC.US)去年第四季業績表現強勁,收入和利潤率均實現增長,分別超出預期5%及59%,公司更宣布增加股東回報,擬斥12.5億美元進行回購。
大和指出,雖然經營層面面對挑戰,但百勝憑藉良好的抗風險能力及對股東回報的承諾,重申對其「買入」評級。
大和指,期內集團進行靈活業務轉型,包括推出更多入門價格的餐點及創新門店形式,相信有助應對2024年宏觀挑戰及競爭。計及市場競爭及門店擴張計劃,該行將今明兩年淨利潤預測下調3%至5%,計及回購因素,將每股盈利預測上調0.1%至3%,目標價從463元降至432元。(gc/u)
~
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.